Novo Nordisk A S (NONOF) community

NONOFOTCPharmaceutical PreparationsFiscal year ends December 31Also trades as NVO

Financials through fiscal 2025, year ended Dec 31, 2025Score 4/30

$38.24−0.60 (-1.53%)

Close on Oct 19, 2026Market cap $170.76BP/E 11.1Yield –

Community

Notes and questions about Novo Nordisk A S from other investors

No posts about NONOF yet

Discussion is coming to every stock. Posts will be able to point at any number on these pages, so everyone sees exactly which figure is being discussed.

Where these numbers come from

Parsed from the XBRL in Novo Nordisk A S's annual and quarterly filings with the SEC
Per-share figures adjusted for the 2-for-1 split on Jan 31, 2024
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is NONOF.

Compare: NONOF vs LLY · NONOF vs RDY · NONOF vs ABT · NONOF vs JNJ · NONOF vs MRK

Revenue growth6.4% · median 8.9%

Gross margin81.0% · median 69.7%

Company	Revenue	Growth
NONOF	309.06B DKK	+6.4%
JNJ	$99.34B	+7.8%
LLY	$86.46B	+45.5%
MRK	$67.38B	+4.9%
ABT	$48.23B	+10.0%
RDY	–	–

Company

Exchange: OTC
Industry: Pharmaceutical Preparations
Fiscal year ends: December 31
Employees: 69,505
Auditor: Deloitte Statsautoriseret Revisionspartnerselskab
SEC CIK: 353278

Advertisement
300 × 250

See a number that looks wrong?